AzTrials
AzTrials

MenopauseEarly Phase 1RISENCT02274571

Raising Insulin Sensitivity in Post Menopause

A Early Phase 1 study testing TSEC (Tissue-selective estrogen complexes) in people with Menopause, run by Pennington Biomedical Research Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to find out if a novel drug approved by the Food and Drug Administration [Duavee™, Pfizer, Inc] for treatment of postmenopausal symptoms (vaginal dryness and hot flashes) and prevention of osteoporosis also improves insulin sensitivity by decreasing body fat especially in your liver. Read more about this study

Who is it for?
Ages 50 to 60 years, women onlyHealthy volunteers can take part
Conditions the study is for
Menopause
What is being tested?
TSEC (Tissue-selective estrogen complexes)
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
8 participants
Where
1 siteUnited States
Study dates
Sep 2015to 11 Apr 2017
Phase
Early Phase 1
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 60 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Post-menopausal women (<5y post last period)
  • Age between 50-60y
  • Symptomatic (hot flashes, vaginal dryness) or asymptomatic
  • BMI 30-40 kg/m2
  • Normal mammogram past 12 months
  • Physician clearance (Ob/Gyn or PBRC)

Who cannot join

  • Amenorrhea other causes (excess androgen)
  • Diabetes mellitus
  • Medications: diabetes, antidepressant uncontrolled depression (2 months stability on SSRIs are fine), antipsychotics, oral steroids, weight loss drugs
  • Tricyclic antidepressants (TCAs)
  • ≤ 3 month washout of birth control pill, estrogen, and/or progestin
  • Hysterectomy (total or partial)
  • Contraindications to estrogen treatment
  • Unable or unwilling to do an MRS

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana, 70808

Other trials in United States

About this study

Official title: Tissue Selective Estrogen Complex to Prevent Metabolic Dysfunction in Women

The purpose of this study is to find out if a novel drug approved by the Food and Drug Administration [Duavee™, Pfizer, Inc] for treatment of postmenopausal symptoms (vaginal dryness and hot flashes) and prevention of osteoporosis also improves insulin sensitivity by decreasing body fat especially in your liver.

DUAVEE™ (Conjugated Estrogens/Bazedoxifene) is a new prescription medicine that contains a mixture of estrogen (the main female hormone made by the ovaries) and bazedoxifene, which is FDA approved. For over 60 years, estrogens have been used as hormonal treatments to help manage hot flashes and help prevent postmenopausal bone loss. But in the treatment of postmenopausal women, the use of estrogens alone can increase the risk of developing cancer of the uterus. So estrogens have been traditionally paired with a progestin to decrease the risk of hyperplasia (the thickening of the lining of the uterus), which can be a precursor to cancer. DUAVEE™ uses bazedoxifene, a selective estrogen receptor modulator (SERM), in place of a progestin to help protect the uterus against thickening of the uterus that may result from estrogens alone.

In this study, you will get either DUAVEE™ or the placebo (a "dummy pill" that may look like medicine but contains no active medication) first and then switch to the other pill.

Read the detailed description

This study involves a screening process to see if you are eligible to participate followed by two 8-week treatment periods separated by an 8-week washout period. The two 8-week treatments will be with:

  1. 8 weeks of treatment with TSEC (Duavee™, combination of CE and BZA)
  2. 8 weeks of treatment with a "dummy pill" (Placebo) The order of these 2 8-week treatment periods will be decided by chance (coin flip). STUDY VISITS (11 VISITS in total) If you participate in this study, after referral from the Baton Rouge General Obstetrics and Gynecology Physicians, you will complete 1 screening visit at Pennington Biomedical Research Center to determine your eligibility. If you are eligible and enrolled in the study, you will complete an additional 10 visits (8 brief visits and 2 overnight inpatient stays). Please note all times provided for procedures and the total times for each clinic visit are approximations and may vary depending on circumstances. SCREENING VISIT (1 visit, approximately 1.5 hours, fasting): Please do not drink any food or water for 10 hours before this appointment. Participants are asked to report to the Pennington clinic fasting. After a detailed explanation of the whole study by a coordinator, if you agree to the procedures by signing a consent form, you will have:
  3. Your height and body weight measured.
  4. You will then have an ECG (electrocardiogram) to measure your heart rate and rhythm.
  5. Your blood pressure will be measured.
  6. A blood sample (<1 teaspoon) and urine will be collected to assess your general health.
  7. You will have a medical history and physical examination. If fully eligible according to the data collected during the screening visit, you will be called to set up a second visit to provide you with the medication or the dummy pill. VISIT 2 (30 minutes): You will come to the Pennington to pick up your drug supply (real medication or dummy pill) and meet with a nurse or a study coordinator to give you instructions on when and how to take your pill once a day. VISITS 3-5 (30 minutes each): At week 1, 3, and 5 of your 8-week treatment period, you will come to our outpatient clinic to measure your weight, blood pressure and pulse, collect some feedback on your health and check your medication compliance as well as distribute new medications. VISIT 6 (24 hours at our inpatient unit): You will be admitted to our inpatient unit at 4pm (not fasted) for measures of:
  8. Total body fat by DXA
  9. Abdominal visceral fat by Magnetic Resonance Imaging (MRI)
  10. Fat in your liver and muscle by Magnetic Resonance Spectroscopy (MRS) You will then receive a standard dinner at ~7pm and will be ask to switch off the light in your bedroom at ~10pm The next morning investigators will wake you up at ~4.45am to start an IV line and start a 8-hour procedure (Euglycemic Clamp) to measure how your body responds to insulin. You will be discharged from the inpatient unit between 2 and 3 pm after being fed a lunch. Visit 1 is Screening; Visit 2/7 is Wk0/17; Visit 3/8 is Wk1/18; Visit 4/9 is Wk3/20; Visit 5/10 is Wk5/22 and Visit 6/11 is Wk8/25 ECG: Screening Vital Signs, Height, Weight, Waist \& Hip Measurements: Screening, Visit 3, Visit 4, Visit 5 \& Visit 6 Fasting Blood \& Urine Sample: Screening and Visit 6 Medical History \& Physical Exam + Questionnaire Barriers: Screening Pick up pills/receive instructions: Visit 2, Visit 3, Visit 4, \& Visit 5 Health Status/Medication Compliance Visit 3, Visit 4 \& Visit 5 Admittance to Inpatient Unit: Visit 6 Body Composition (DXA): Visit 6 Body Composition (MRI): Visit 6 Liver/Muscle Fat (MRS): Visit 6 Euglycemic Clamp with biopsies: Visit 6 Eight weeks later (during which you will not take any pill), you will start the same sequence of visits (VISITS 7-11) as shown above for Visits 2-6 but this time with the other pill. DESCRIPTION OF PROCEDURES Euglycemic IV clamp (8 hours): This procedure measures how the body responds to insulin. Insulin is normally produced by your body during meals and helps your body use sugar. There will be 2 IV lines, one in your arm and one in your hand on the opposite side. Approximately 30 minutes after the IV lines are inserted; investigators will perform a fat biopsy to sample fat cells beneath the skin of your stomach area. Then, a muscle biopsy will be obtained to sample muscle cells beneath the skin of your thigh. Small amounts of glucose and insulin will be infused into your arm. Your blood sugar level will be checked every 5-10 minutes from the IV in your hand to determine how much glucose you should have to keep your blood sugar at a normal level. Your hand will be placed inside a warming box to increase skin temperature to about 105 degrees Fahrenheit. The temperature will be warm, but not uncomfortable. During your IV procedure, a small amount of your own blood (less than 1 teaspoon) will immediately be returned into your vein through the IV after each specimen is collected Three times during the 8-hour procedure, investigators will place a clear plastic hood, through which fresh air flows, over your head to measure how many calories your body burns. This measure will last 40 minutes each time. Your urine will be collected throughout the test in a urine jug (at the end of the test or in 2 collections if necessary). Fat biopsy (about 30 minutes): This procedure is used to sample fat cells from underneath the abdominal skin after cleansing the skin with iodine and using a local anesthetic. After cleansing the area, the doctor or Nurse Practitioner will make a small incision in the skin and introduce a needle under the skin to remove fat cells. About 1 gram (less than half a teaspoon size) of fat will be removed. After the biopsy is completed, the skin will be held closed with a sterile adhesive bandage; an antibiotic ointment will be applied. Risks: Fat Biopsy: Mild to severe pain, soreness, and bruising, and a small scar are common risks. There is a small risk of a hematoma (collection of blood in the tissue) or infection at the biopsy site. Sterile technique will be used to minimize these risks and the biopsy site will be monitored closely. Muscle Biopsy (about 30 minutes): This procedure is used to sample muscle cells from underneath the skin of the leg. After cleaning the skin with iodine and using a local anesthetic, the doctor or nurse practitioner will make a small incision in the skin and introduce a needle under the skin to remove muscle cells. About 200-750 milligrams (less than a teaspoon size) of muscle will be removed. After the biopsy is completed, the skin will be held closed with a sterile adhesive bandage and an antibiotic ointment will be applied. Risks: Muscle Biopsy: Mild to severe pain, soreness, bruising, and a small scar are common risks. A hematoma (collection of blood in the tissue) may occur. There is a slight risk that a superficial nerve may be cut; the nerve may heal, or it may result in a permanent loss of sensation in the skin at the biopsy site. DXA - Whole Body Scan (~4 minutes): This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table. A scanner emitting low energy X-rays and a detector will pass along your body. You will be asked to remain completely still while the scan is in progress. The scan takes less than four minutes. This scan is for research purposes only and not for diagnostic treatment. MRI Abdomen (30 minutes): This scan measures the amount of fat in your abdomen. You will change into a hospital gown and remove all objects containing metal from your body. You will lie on your back on the scanner table with your arms above your head. A large coil will be placed around your upper abdomen. You will then be moved into the magnet and will be instructed to hold your breath 4-5 times (once for six seconds, once for 13 seconds, and 2-3 times for about 18 seconds after the upper abdominal scans are completed, you will be moved up on the table, and the coil will be placed over your lower abdomen. The same scans will be acquired over this area with the same 4-5 breath holds. The total scan time for this procedure is approximately 30 minutes. During the scan, you will hear loud tapping noises. You will be given headphones for protection from the scanner noise and can listen to music during the scan if desired. You will also be given a call button should you need the MRI Technician during the exam. This scan is for research purposes only and not for diagnostic treatment. MRS IHL (Intrahepatic lipid) (20-30 minutes): This scan measures the amount of fat in your liver. You will change into a hospital gown and remove all objects containing metal from your body. You will be placed on the scanner table head first and on your stomach. The table will move you into the magnet where data will be obtained. The scan will last for approximately 20-30 minutes. During the scan, you will hear loud tapping noises. You will be given head phones for protection from the scanner noise and can listen to music during the scan if desired. You will also be given a call button should you need the MRI tech during the exam. This scan is for research purposes only and not for diagnostic treatment. MRS IMCL (Intramyocellular lipid) (60 minutes): This scan measures the amount of fat in your muscle fibers. You will change into a hospital gown and remove all objects containing metal from your body. You will lie on your back on the scanner table with the right leg in a special coil. The top part of the coil will then be placed over your calf. Cushions will be inserted around the calf to help keep the leg as still as possible. The table will then move you into the scanner where a series of several scans will be obtained. The entire procedure will last approximately 60 minutes. During the scan, you will hear loud tapping noises. You will be given head phones for protection from the scanner noise and can listen to music during the scan if desired. You will also be given a call button should you need the MRI tech during the exam. This scan is for research purposes only and not for diagnostic treatment.
Conditions
Menopause
Being tested
TSEC (Tissue-selective estrogen complexes), Placebo

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TSEC (Tissue-selective estrogen complexes)Drug

    Also called Duavee™

    Duavee™, combination of CE(conjugated equine estrogens) and BZA (bazedoxifene)

  • PlaceboOther

    non active

Study groups in NCT02274571
Study groupRoleWhat they receive
DrugExperimentalTSEC (Duavee™, combination of CE and BZA)
Receives: Drug: TSEC (Tissue-selective estrogen complexes); Other: Placebo
PlaceboPlacebo comparatorNon active comparator
Receives: Drug: TSEC (Tissue-selective estrogen complexes); Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Effect of CE/BZA (TSEC) on Body Composition

    Measured: 8 weeks

  2. Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance Spectroscopy

    Measured: 8 weeks

  3. Effect of CE/BZA (TSEC) on Abdominal Fat Cell Size (by Biopsy)

    Measured: 8 weeks

  4. Effect of CE/BZA (TSEC) on Body Mass Index

    Measured: 8 weeks

  5. Effect of CE/BZA (TSEC) on Percent Body Fat

    Measured: 8 weeks

  6. Effect of CE/BZA (TSEC) on Fat Cell Ratio (Small/Large)

    Measured: 8 weeks

  7. Effect of CE/BZA (TSEC) on Mean Fat Cell Size

    Measured: 8 weeks

Secondary outcomes (9)
  1. Effect of CE/BZA (TSEC) on Fasting Labs

    Measured: 8 weeks

  2. Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp)

    Low-Dose Insulin [20 mIU/min/m2 ], High-Dose Insulin [120 mIU/min/m2 ]

    Measured: 8 weeks

  3. Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on FFA

    Low-Dose Insulin [20 mIU/min/m2 ] High-Dose Insulin [120 mIU/min/m2 ]

    Measured: 8 weeks

  4. Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)

    Measured: 8 weeks

  5. Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)

    Low-Dose Insulin [20 mIU/min/m2 ], High-Dose Insulin [120 mIU/min/m2 ]

    Measured: 8 weeks

  6. Effect of CE/BZA (TSEC) on Fasting Insulin

    Measured: 8 weeks

  7. Effect of CE/BZA (TSEC) on Fasting Free Fatty Acids

    Measured: 8 weeks

  8. Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Glucose

    Low-Dose Insulin [ 20 mIU/min/m2 ]

    Measured: 8 weeks

  9. Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Insulin

    Low-Dose Insulin [20 mIU/min/m2 ] High-Dose Insulin [120 mIU/min/m2 ]

    Measured: 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Oct 2014 (estimated)
  2. Study startSep 2015
  3. Primary completion11 Apr 2017
  4. Study completion11 Apr 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
8 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02274571
Sponsor's protocol ID
PBRC 2014-039
Acronym
RISE
Status last verified
May 2025
First submitted
22 Oct 2014
Last updated
4 Jun 2025
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing TSEC (Tissue-selective estrogen complexes) in people with Menopause, run by Pennington Biomedical Research Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 4 Jun 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Effect of CE/BZA (TSEC) on Body Composition (time frame: 8 weeks). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in